RxDoctor Payments Data

Genri Pinkhasov, MD

Urology · Valparaiso, INNPI 1639370893

Payments from drug & device makers

$1,660in general payments, 2019–2025

Across 73 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$459
  • Olympus America Inc.$222
  • AbbVie$151
  • Boston Scientific$147
  • 180 Medical, Inc.$133
  • Johnson & Johnson$93
  • plus $456 from 15 others

What the payments were for

  • Food & beverage$1,47889%
  • Education$18211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,660 in reported general payments places this provider in the 35th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$207,883
Medicare patients
500
Services billed
2,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron16$19,757
Tamsulosin Hcl472$6,691
Tolterodine Tartrate ErTolterodine Tartrate37$4,839
Finasteride362$4,438
Potassium Citrate ErPotassium Citrate17$2,317
Bicalutamide42$907
Oxybutynin Chloride60$546
Oxybutynin Chloride ErOxybutynin Chloride13$433
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim116$187
Ampicillin Trihydrate13$174
Cephalexin37$141
Ciprofloxacin Hcl50$138
Terazosin Hcl13$120
Alfuzosin Hcl ErAlfuzosin Hcl22$106
Allopurinol15$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$459$19,75716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 272 urology providers in Indiana.

Other urology in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →